Renova Pharmaceuticals LLC announced today that the FDA has approved intravesical dimethyl sulfoxide for medical use, a formulation that may enter a niche market for managing pain associated with specific interstitial cystitis and could alter treatment protocols in urology. This approval marks a significant therapeutic milestone for the company, validating their generic briding strategy and broadening their revenue streams within the chronic pain management sector.